|
CAS Number |
1050477-31-0 |
|
Purity |
≥98% |
|
Total impurity |
≤2% |
|
Single impurity |
≤0.5% |
|
Molecular Formula |
C21H22N4O3 |
|
Molecular Weight |
378.42 |
|
Retesting period |
12 months |
|
Storage Condition |
Sealed storage |
|
COA/ROS/MSDS/MOA |
Provided |
Finerenone is a novel mineralocorticoid receptor antagonist that has the effect of delaying the progression of chronic kidney disease. Some people may be aware of two other mineralocorticoid receptor antagonists: the diuretic antihypertensive drug spironolactone, and eplerenone.Finerenone is their cognate derivative and is a third-generation mineralocorticoid receptor antagonist. So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved. Finerenone was granted FDA approval on 9 July 2021, followed by the EMA approval on 11 March 2022.
Finerenone is the first non-steroidal selective mineralocorticoid receptor antagonist, which can be used for the treatment of diabetic nephropathy, chronic kidney disease and end-stage renal disease. It can reduce the proteinuria of patients and improve the glomerular filtration rate.
Finerenone (FIN, BAY 94-8862) is a highly selective, orally active, nonsteroidal antagonist of mineralocorticoid receptor (MR) with IC50 of 18 nM. Finerenone has the potential to study cardio-renal diseases such as type 2 diabetes and chronic kidney disease.
Hot Tags: finerenone (bay 94-8862), China finerenone (bay 94-8862) suppliers, factory
